Cancer in Cavemen?

Article

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent case report of a 1.7-million-year-old osteosarcoma found in an extinct human lineage.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent case report of a 1.7-million-year-old osteosarcoma found in an extinct human lineage.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.
Treatment with afami-cel may offer improved quality of life to patients with metastatic synovial sarcoma compared with continuous chemotherapy.
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
Related Content
Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.

Diagnosing and Treating Patients With Epithelioid Sarcoma

ONCOLOGY Staff
July 4th 2025
Article

Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.

Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.

Afami-cel Approval May Open Gateway for Synovial Sarcoma Advancements

Brian Van Tine, MD, PhD
August 26th 2024
Podcast

Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.

Results from the phase 3 DeFi trial showed superior progression-free survival with nirogacestat vs placebo in patients with progressing desmoid tumors.

Nirogacestat Receives Positive Opinion from CHMP in Desmoid Tumors

Tim Cortese
June 20th 2025
Article

Results from the phase 3 DeFi trial showed superior progression-free survival with nirogacestat vs placebo in patients with progressing desmoid tumors.

Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.

Sarcoma Awareness Month 2023 with Brian Van Tine, MD, PhD

Brian Van Tine, MD, PhD
August 1st 2023
Podcast

Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

FDA Grants THE001 Orphan Drug Designation for Soft Tissue Sarcomas

Roman Fabbricatore
May 12th 2025
Article

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

ONCOLOGY Staff
April 18th 2025
Article

Personalized therapeutic approaches and novel, targeted medicines can help patients with epithelial sarcoma attain better survival outcomes.